# Association between obstructive sleep apnea and venous thromboembolism recurrence: results from a French cohort

Olivier Nepveu, Charles Orione, Cécile Tromeur, Alexandre Fauché, Cecile L'heveder, Marie Guegan, Catherine Lemarié, David Jimenez, Christophe Leroyer, Karine Lacut, et al.

<figure><img src="image_1.png" /></figure>

## To cite this version:

Olivier Nepveu, Charles Orione, Cécile Tromeur, Alexandre Fauché, Cecile L'heveder, et al. Associa-
tion between obstructive sleep apnea and venous thromboembolism recurrence: results from a French
cohort. Thrombosis Journal, 2022, 20 (1), 10.1186/s12959-021-00358-8. hal-04758089

HAL Id: hal-04758089

https://hal.univ-brest.fr/hal-04758089v1

Submitted on 29 Oct 2024

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_2.png" /></figure>

Distributed under a Creative Commons Attribution 4.0 International License
RESEARCH

Open Access

<figure><img src="image_3.png" /></figure>

Check for
updates

# Association between obstructive sleep apnea and venous thromboembolism recurrence: results from a French cohort

Olivier Nepveu<fnref n="1" />,<fnref n="2" />, Charles Orione<fnref n="1" />,<fnref n="2" />, Cécile Tromeur<fnref n="1" />,<fnref n="2" />, Alexandre Fauché<fnref n="1" />,<fnref n="2" />, Cecile L'heveder<fnref n="1" />,<fnref n="2" />, Marie Guegan<fnref n="1" />,<fnref n="2" />, Catherine Lemarié<fnref n="1" />,<fnref n="2" />, David Jimenez³, Christophe Leroyer<fnref n="1" />,<fnref n="2" />, Karine Lacut<fnref n="1" />,<fnref n="2" />, Francis Couturaud<fnref n="1" />,<fnref n="2" /> and Raphael Le Mao<fnref n="1" />,<fnref n="2" />*

## Abstract

**Background:** Growing evidence suggests the relationship between obstructive sleep apnea (OSA) and venous thromboembolism (VTE). Few studies focused on VTE recurrence risk associated with OSA after anticoagulation cessation.

**Methods:** In a prospective cohort study, patients with documented VTE, were followed for an indefinite length of time and VTE recurrence were documented and adjudicated. The primary outcome was recurrent VTE after anticoagulation discontinuation. Secondary outcomes included all-cause mortality and the clinical presentation of VTE. Univariable and multivariable analyses were performed to identify risk factors for recurrence and mortality.

**Results:** Among the 2109 patients with documented VTE included, 74 patients had moderate to severe OSA diagnosis confirmed by home sleep test or polysomnography. During a median follow-up of 4.8 (interquartile range 2.5–8.0) years recurrent VTE occurred in 252 patients (9 with OSA and 243 without OSA). The recurrence risk in the univariable and multivariable analysis was not increased in patients with OSA, regardless of the time of diagnosis (before or after index VTE or pooled). VTE phenotype was significantly more often PE with or without associated deep vein thrombosis in the first event and recurrence for OSA patients compared to non-OSA patients. The risk of death was not increased in the OSA population compared to non-OSA patients in multivariable analysis.

**Conclusions:** In patients with OSA and VTE, the risk of all-cause mortality and VTE recurrence after anticoagulation discontinuation was not increased compared to non-OSA patients.

## Introduction

Venous thromboembolism (VTE), including pulmonary embolism (PE) and deep vein thrombosis (DVT), is a major health issue. PE is the most common cardiovascular cause of death after myocardial infarction and stroke

[1] with an annual incidence of 0.69/1000 [2, 3]. The most frequent complication is VTE recurrence (10% at 1 year, 25% at 5 years for unprovoked VTE), with a mortality rate of 4% [4]. Identifying transient or permanent risks factor of VTE is the cornerstone of medical care of patients [5].

Obstructive sleep apnea (OSA), characterized by periodic narrowing and obstruction of the pharyngeal airway during sleep [6], is also a common disease (3 to 10% of the general population) [7–9], probably underestimated [10] and associated with the onset of cardiovascular and

<footnote>* Correspondence: raphael.lemao@gmail.com</footnote>

<footnote n="1">¹Groupe d'Etude de la Thrombose de Bretagne Occidentale, UMR 1304, INSERM, Département de médecine vasculaire, interne et pneumologie, Centre hospitalo-universitaire de Brest, Université de Bretagne Occidentale, CHRU de Brest, 29609 Brest, Cedex, France</footnote>

<footnote n="2">²Centre d'Investigation Clinique INSERM 1412, Brest, France
Full list of author information is available at the end of the article</footnote>
metabolic comorbidities [11–17]. VTE and OSA have some risk factors in common such as age, obesity and immobility [18].

There is a growing evidence suggesting that OSA is a risk factor of VTE [19, 20]. Several physiological studies have explored and demonstrated the effect of OSA on coagulation and suggested that OSA induced a pro-thrombotic state, an oxidative stress, a chronic inflammation and vasoconstriction, increased coagulation factors, and altered fibrinolysis [20]. Moreover, obesity is frequently associated with OSA (up to 45% of OSA diagnosis in obese patients) [21] and is also a risk factor of VTE [22–24]. OSA prevalence is higher in patients with previous VTE compared to the general population [25]. Concerning the association between OSA and VTE recurrence, Alonso-Fernandez et al., in a case-control study including 107 patients with PE and 102 patients without VTE, showed that OSA was more frequent in patients with PE and for every 10-unit rise in apnea-hypopnea index (AHI), the PE risk increased by 45% [26]. Though this study suggested an increased risk of VTE recurrence in OSA patients, prospective studies showed some conflicting results regarding VTE recurrence risk [27–29].

In the present study, we aimed to assess the association between OSA and recurrent VTE after a first event of VTE and anticoagulation discontinuation. We analyzed, as well, the correlation between AHI and nocturnal desaturation with thrombotic risk and the impact of OSA on mortality.

# Methods

## Study design

Consecutive patients with objectively diagnosed VTE in four French Hospital Centers were included in a prospective multicenter cohort study [30–32]. All cases had an unlimited follow-up with the annual clinical information collection. All VTE cases that occurred between May 2000, and June 2019 were included in the present report.

## Patient selection

Consecutive patients hospitalized or referred to Hospital outpatient VTE clinics for documented VTE (e.g., an isolated symptomatic DVT or symptomatic PE associated or not to DVT) who discontinued anticoagulation after VTE and during follow-up were potentially eligible. Patients were then indexed at time of anticoagulation discontinuation.

## Index VTE diagnosis

The diagnosis of VTE was performed using objective, standardized and validated criteria (45,46). Symptomatic DVT was confirmed in case of a non-compression of

deep veins of the legs using real-time B mode ultrasound. Symptomatic PE was confirmed if there was: (i) a high clinical probability and a high-probability ventilation-perfusion lung scan according to the PIOPED criteria, or (ii) a proximal DVT showed by ultrasonography in a patient with symptoms of PE, or (iii) a positive computed tomography pulmonary angiography (CTPA) showing a central filling defect outlined by contrast material or complete occlusion in a segmental or more proximal pulmonary artery. VTE was classified, according to recent french guidelines, as provoked in the presence of at least one of the following transient or persistent major risk factors: surgery or immobilization in the past three months, pregnancy or post-partum in the past three months, cancer, administration of an estrogen-containing pill, hormone replacement therapy, pregnancy or the post-partum period within the previous 3 months [33]. VTE was considered as unprovoked in the absence of all these risk factors.

## OSA identification

In this study, we focused on moderate to severe OSA in order to select a homogeneous population of patients supposed to be at higher risk of VTE events. OSA was therefore defined in high probability pretest for sleep apnea, when AHI was greater than 15 or patient with OSA diagnosis requiring dedicated device (i.e., continuous positive airway pressure or non-invasive ventilation). To identify all patients with respiratory diseases and OSA, research by ICD 10 code and keywords was conducted in the Brest University Hospital database and crossed with the cohort study database. The use or initiation of CPAP or NIV in the 12-months following the diagnosis was also collected but without collecting initiation date. The diagnosis of OSA was confirmed for each patient based on medical records, seeking pulmonary functional tests, home sleep tests, and polysomnography results by one or two experienced physician(s). In the case of missing HST and polysomnography (PSG) results in our database, missing data were collected directly from the patient's pulmonologist records. As well, OSA diagnosis was confirmed two times. In the analysis, we distinguished two groups of OSA patients: "OSA-history" was defined as those with OSA diagnosed prior to index VTE event and "OSA-occurrence" as those with OSA diagnosed after the index VTE event.

## Follow-up

All patients were prospectively followed up to five years, with an annual collection of clinical, biochemical, and morphological data. Interviews were conducted initially and during follow-up using the same standardized questionnaire. After the first 3 to 6 months of anticoagulant treatment, patients were followed systematically annually
through a dedicated visit or a phone call. Investigations were made in case of missing follow-up to assess the patient's health status.

## Outcomes

The primary outcome was symptomatic VTE recurrence up to 5 years of follow-up after anticoagulation discontinuation. Recurrent VTE was defined by (i) a symptomatic non-fatal recurrent PE, or (ii) a symptomatic recurrent DVT, or (iii) a fatal recurrent PE. The diagnosis of recurrent DVT was confirmed using real B mode leg ultrasound in case of initial DVT extension, contra-lateral recurrence of DVT, or ipsilateral DVT recurrence. The diagnosis of recurrent PE was confirmed by (i) a segmental or a more proximal thrombus on CTPA, (ii) the presence of at least one new perfusion defect of at least 75% in contrast with normal ventilation, (iii) a clinical suspicion of PE associated with a recurrent proximal DVT. The secondary outcomes were overall mortality and the phenotype of recurrent VTE (i.e., PE versus DVT). Physicians not involved in the patient's medical care adjudicated all initial VTE events, recurrences, and deaths.

## Statistical analysis

Continuous variables were expressed as mean (standard deviation [SD]) and median (interquartile range [IQR]); categorical variables were expressed as numbers and percentages. The student t-test was used to compare means between groups in case of normal distribution and the Mann-Whitney test in non-normal distribution. A Chi-square test or exact Fisher test was used to compare proportions as appropriate.

The rates of recurrent VTE were estimated using the Kaplan Meier method. An univariable Cox proportional hazard model analysis was performed to identify risk factors of recurrent VTE and death. Hazard ratio (HR) with 95% confident interval (CI) were provided. Multivariable analyses were performed using cause specific Cox models in two stages for the risk of recurrent VTE as well as for the risk of death (competitive risk) in association with OSA. The first multivariable model was constructed by including variables whose distribution was statistically different (*p* < 0.05) between the two groups. The second multivariable model was constructed by including (i) variables associated with increased risk of recurrence or death in univariable analysis, with *p*-value < 0.15 and a frequency > 3%; and (ii) variables whose distribution was significantly different between the two groups (*p* < 0.05). In multivariable models, risk factors were considered independent for a *p*-value < 0.05. All tests were two-sided. Statistical analyses were performed using R software Version 1.0.153 –© 2009–2017 RStudio, Inc.

## Ethics statement

This study was conducted following the amended Declaration of Helsinki. The Ethics Committee of Brest University Hospital approved the study protocol (IRB approval number: CCP Ouest 6–390). Written informed consent was obtained from all participants before inclusion.

## Results

Between May 2000 and June 2019, 4452 patients with objectively confirmed VTE were enrolled and prospectively followed-up. Among them, 2343 patients were excluded for the following reasons: long term anticoagulation (*n* = 1908), a recurrent VTE (*n* = 352), age under 18 years old (*n* = 19), and without follow up (*n* = 64) (Fig. 1). A total of 2109 patients (932 men, 1177 women) were included in the analysis.

## Baseline characteristics

Overall, 74 patients had OSA objectively confirmed by the home sleep test of polysomnography. Patients with OSA were older, predominantly obese or overweight, with history of cardiovascular and pulmonary disease. Sixty-three of them (85%) had a dedicated device (NIV or CPAP) for OSA. VTE was generally unprovoked, and clinical presentation was more often PE rather than DVT in OSA patients. Concomitant treatment (i.e., statin, antiplatelet agents) and anticoagulant therapy length were not significantly different between the two groups. The mean (standard deviation SD) follow-up of the overall population was 5.6 (4.2) years, 5.6 (4.2) years in the non-OSA group, and 5.4 (4.2) years in the OSA group (*p* = 0.70). Demographic and clinical characteristics at inclusion are presented in Table 1.

## Risk of recurrent VTE

The 5-year cumulative incidence rates of recurrent VTE were not statistically different (*p* = 0.38) between patients with: (i) OSA history (19.2% (95% CI, 3.9–32.1); (ii) OSA occurrence (4.3% (95% CI, 0.0–12.3)); (iii) and patients without OSA (12.4% (95% CI, 10.8–13.9)).

In univariable analysis, OSA diagnosed prior index VTE (HR 1.46 (95% CI, 0.69–3.09); *p* = 0.33), OSA diagnosed after index VTE (HR 2.78 (95% CI, 0.68–11.32); *p* = 0.328), AHI and nocturnal desaturation were not associated with an increased risk of recurrence (Table 2).

In multivariable model 1, which included variables associated with an increased risk of recurrence in univariable analysis, the risk of recurrent VTE was not significantly increased in patients with OSA history (HR 1.37 (95% CI, 0.64–2.94); *p* = 0.46) or OSA occurrence (HR 2.34 (95% CI, 0.57–9.62); *p* = 0.24) as compared to other patients (Table 2). In multivariable model 2, which included baseline characteristics distributed differently
<figure><img src="image_4.png" /><figcaption>**Fig. 1** Flow chart. OSA, Obstructive Sleep Apnea; VTE, Venous Thromboembolism</figcaption></figure>

between OSA and non-OSA patients, and variables associated with an increased risk of recurrence in univariable analysis, the predictors of recurrent VTE were similar to those found in the first multivariable model (Table 2). The main risk factors of recurrence were older age, unprovoked VTE, and cancer. Similar results were observed in sensitivity analysis on the risk of recurrent VTE in patients with pooled diagnosis of OSA (eTable 1).

## Index and recurrent VTE clinical presentation

Recurrent VTE occurred in 252 patients during the follow-up after anticoagulation discontinuation; nine of these recurrences occurred in OSA patients and 243 in non-OSA patients (Table 3). Among the 252 recurrences of VTE, 125 (49,6%) were isolated DVT, 63 (25%) were isolated PE, 64 (25,4%) were PE with DVT (Table 3).

The clinical presentation of index VTE and recurrent VTE were statistically different: 1117 (55%) patients without OSA and 51 (68.9%) patients with OSA had an index PE with or without DVT (p = 0.023), 120 (49.4%) patients without OSA and seven patients (77.8%) patients with OSA had a recurrent VTE as PE with or without DVT (p = 0.09).

## Mortality

During follow-up, death from any cause occurred in 155 (7.3%) patients: 2 of the 74 OSA patients (2.7%) and 153 of 2035 non-OSA patients (7.5%) (p = 0.295). In univariable analysis, there was no increased risk of death in patients with a history of OSA compared to non-OSA patients (HR 0.75 (95% CI, 0.19–3.02); p = 0.70) (eTable 2). AHI was not associated with an increased risk of

death as well as nocturnal desaturation. After adjustment on variable associated with mortality in univariable analysis, the risk of death was not greater in OSA history patients as compared to other patients (HR 0.18 (95% CI, 0.02–1.31); p = 0.09) (eTable 2).

## Discussion

In the present study, including 2109 patients with acute symptomatic VTE, followed-up after anticoagulation discontinuation, the presence of OSA diagnosed before or after index VTE, treated by CPAP in the majority of cases (85%) was not significantly associated with an increased risk of VTE recurrence, nor with increased overall mortality, as well as AHI and nocturnal desaturation.

Although OSA could be considered as a chronic syndrome with exposition to intermittent hypoxemia over the years before treatment and diagnosis, we considered two groups of patients, one with a history of OSA before the index VTE and one with an occurrence of OSA after the index VTE to evaluate its effect over the time. We found that OSA's occurrence tended to increase the recurrence risk compared to OSA's history. The effect of OSA pooled, as one variable was similar.

Alonso-Fernández et al. evaluated the association between OSA and the risk of recurrent PE after anticoagulation discontinuation in 120 patients with a first episode of PE [28]. OSA was identified after index VTE in 71 patients. OSA was associated with an increased risk of VTE recurrence (HR 4.05 (95% CI, 1.18–13.91) p = 0.026). Firstly, OSA was diagnosed with HST after PE, while in the present study, most OSA diagnoses were made before index VTE. However, there was no difference statistically significant in the risk of recurrent
<table><caption>**Table 1** Baseline characteristics</caption><thead><tr><th>Variables</th><th></th><th>Total</th><th>Non-OSA patients</th><th>OSA patients</th><th>p-value</th></tr></thead><tbody><tr><td>Age (years)</td><td>Mean (SD)</td><td>56.75 (19.4)</td><td>56.53 (19.6)</td><td>62.67 (13.3)</td><td>0.008</td></tr><tr><td>Age (years)</td><td>n (%)</td><td></td><td></td><td></td><td>0.002</td></tr><tr><td></td><td>≤ 50</td><td>805 (38.2)</td><td>790 (38.8)</td><td>15 (20.3)</td><td></td></tr><tr><td></td><td>50-65</td><td>464 (22.0)</td><td>439 (21.6)</td><td>25 (33.8)</td><td></td></tr><tr><td></td><td>> 65</td><td>839 (39.8)</td><td>805 (39.6)</td><td>34 (45.9)</td><td></td></tr><tr><td>Gender</td><td>Female n (%)</td><td>1177 (55.8)</td><td>1151 (56.6)</td><td>26 (35.1)</td><td>&lt; 0.001</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td>Mean (SD)</td><td>26.27 (5.0)</td><td>26.10 (4.9)</td><td>30.90 (5.5)</td><td>&lt; 0.001</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td>n (%)</td><td></td><td></td><td></td><td>&lt; 0.001</td></tr><tr><td></td><td>≤ 25</td><td>917 (44.4)</td><td>908 (45.6)</td><td>9 (12.5)</td><td></td></tr><tr><td></td><td>> 25 - ≤ 30</td><td>763 (36.9)</td><td>735 (36.9)</td><td>28 (38.9)</td><td></td></tr><tr><td></td><td>> 30 - ≤ 35</td><td>268 (13.0)</td><td>252 (12.6)</td><td>16 (22.2)</td><td></td></tr><tr><td></td><td>> 35</td><td>117 (5.7)</td><td>98 (4.9)</td><td>19 (26.4)</td><td></td></tr><tr><td>Smoking</td><td>n (%)</td><td>973 (47.0)</td><td>936 (46.9)</td><td>37 (51.4)</td><td>0.53</td></tr><tr><td>Atrial fibrillation</td><td>n (%)</td><td>58 (2.8)</td><td>55 (2.8)</td><td>3 (4.2)</td><td>0.71</td></tr><tr><td>Chronic heart failure: n (%):</td><td>n (%)</td><td>134 (6.4)</td><td>125 (6.1)</td><td>9 (12.2)</td><td>0.07</td></tr><tr><td>Kidney failure</td><td>n (%)</td><td>83 (3.9)</td><td>73 (3.6)</td><td>10 (13.5)</td><td>&lt; 0.001</td></tr><tr><td>Stroke</td><td>n (%)</td><td>68 (3.2)</td><td>55 (2.7)</td><td>13 (17.6)</td><td>&lt; 0.001</td></tr><tr><td>Characteristics of index VTE</td><td>n (%)</td><td></td><td></td><td></td><td>0.032</td></tr><tr><td></td><td>Isolated PE</td><td>558 (26.5)</td><td>530 (26.1)</td><td>28 (37.8)</td><td></td></tr><tr><td></td><td>PE associated with DVT</td><td>610 (29.0)</td><td>587 (28.9)</td><td>23 (31.1)</td><td></td></tr><tr><td></td><td>Isolated DVT</td><td>934 (44.4)</td><td>911 (44.9)</td><td>23 (31.1)</td><td></td></tr><tr><td>Characteristics of recurrent VTE</td><td>n (%)</td><td></td><td></td><td></td><td>0.23</td></tr><tr><td></td><td>Isolated PE</td><td>63 (25.0)</td><td>61 (25.1)</td><td>2 (22.2)</td><td></td></tr><tr><td></td><td>PE associated with proximal DVT</td><td>44 (17.5)</td><td>40 (16.5)</td><td>4 (44.4)</td><td></td></tr><tr><td></td><td>PE associated with distal DVT</td><td>20 (7.9)</td><td>19 (7.8)</td><td>1 (11.1)</td><td></td></tr><tr><td></td><td>Isolated proximal DVT</td><td>84 (33.3)</td><td>83 (34.2)</td><td>1 (11.1)</td><td></td></tr><tr><td></td><td>Isolated distal DVT</td><td>41 (16.3)</td><td>40 (16.5)</td><td>1 (11.1)</td><td></td></tr><tr><td>Anticoagulant duration</td><td>n (%)</td><td></td><td></td><td></td><td>0.37</td></tr><tr><td></td><td>≤ 90 days</td><td>190 (9.0)</td><td>184 (9.1)</td><td>6 (8.1)</td><td></td></tr><tr><td></td><td>> 90 - ≤ 180 days</td><td>543 (25.8)</td><td>527 (25.9)</td><td>16 (21.6)</td><td></td></tr><tr><td></td><td>> 180 - ≤ 360 days</td><td>895 (42.5)</td><td>866 (42.6)</td><td>29 (39.2)</td><td></td></tr><tr><td></td><td>> 360 days</td><td>478 (22.7)</td><td>455 (22.4)</td><td>23 (31.1)</td><td></td></tr><tr><td>Unprovoked VTE</td><td>n (%)</td><td>1199 (56.9)</td><td>1148 (56.4)</td><td>51 (68.9)</td><td>0.044</td></tr><tr><td>Provoked VTE</td><td>n (%)</td><td>910 (43.1)</td><td>887 (43.6)</td><td>23 (31.1)</td><td></td></tr><tr><td>Aspirin</td><td>n (%)</td><td>215 (10.2)</td><td>203 (10.0)</td><td>12 (16.2)</td><td>0.12</td></tr><tr><td>Statin</td><td>n (%)</td><td>192 (9.1)</td><td>181 (8.9)</td><td>11 (14.9)</td><td>0.12</td></tr><tr><td>CPAP</td><td>n (%)</td><td>63 (69.2)</td><td>0 (0.0)</td><td>63 (85.1)</td><td>&lt; 0.001</td></tr><tr><td>OSA history</td><td>n (%)</td><td>46 (2.2)</td><td>0 (0.0)</td><td>46 (2.2)</td><td></td></tr><tr><td>OSA occurrence</td><td>n (%)</td><td>28 (1.3)</td><td>0 (0.0)</td><td>28 (1.3)</td><td></td></tr><tr><td>PSG or HST n (%)</td><td>Mean (SD)</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>Total number of apneas</td><td>88.50 (105.4)</td><td>15.64 (22.6)</td><td>114.00 (111.2)</td><td>0.002</td></tr><tr><td></td><td>Number of apneas by hours</td><td>11.92 (14.4)</td><td>1.81 (2.9)</td><td>15.37 (15.2)</td><td>0.002</td></tr><tr><td></td><td>Number of obstructive apneas</td><td>59.58 (80.8)</td><td>6.93 (11.1)</td><td>78.97 (86.7)</td><td>0.003</td></tr></tbody></table>
<table><caption>**Table 1** Baseline characteristics (Continued)</caption><thead><tr><th>Variables</th><th>Total</th><th>Non-OSA patients</th><th>OSA patients</th><th>p-value</th></tr></thead><tbody><tr><td>Number of central apneas</td><td>6.40 (17.5)</td><td>1.93 (4.9)</td><td>8.05 (20.1)</td><td>0.27</td></tr><tr><td>Number of mixed apneas</td><td>8.92 (19.8)</td><td>1.21 (2.2)</td><td>11.76 (22.6)</td><td>0.09</td></tr><tr><td>Apnea hypopnea index by hour</td><td>31.82 (20.8)</td><td>8.15 (4.3)</td><td>38.88 (18.4)</td><td>&lt; 0.001</td></tr><tr><td>Nocturnal Desaturation</td><td></td><td>17 (0.8)</td><td>57 (77.0)</td><td></td></tr><tr><td>Mean (SD)</td><td></td><td></td><td></td><td></td></tr><tr><td>Percentage of time &lt; 90%</td><td>29.73 (31.3)</td><td>21.41 (32.4)</td><td>32.51 (30.7)</td><td>0.24</td></tr><tr><td>Percentage of time &lt; 85%</td><td>11.26 (22.1)</td><td>8.71 (23.0)</td><td>12.08 (22.0)</td><td>0.63</td></tr><tr><td>Percentage of time &lt; 80%</td><td>3.35 (12.1)</td><td>0.08 (0.3)</td><td>4.42 (13.8)</td><td>0.27</td></tr></tbody></table>

BMI body mass index, CPAP continuous positive airway pressure, OSA Obstructive Sleep Apnea, PSG polysomnography, HST Home Sleep Tests, VTE Venous Thromboembolism

VTE between OSA diagnosed before and after index VTE. Secondly, AHI ≥ 10/h was identified as an independent risk factor, but AHI ≥ 30/h was not. In the present study, OSA diagnosis was mainly severe OSA:

the mean (SD) AHI (h-1) was higher (38.88 ± 18.4 vs 21.1 ± 20.5), the mean (SD) desaturation index (h-1) was higher (41.62 ± 35.15 vs 18.3 ± 19.7), and CPAP treatment was more frequent in OSA patients (63 of 74

<table><caption>**Table 2** Risk factor for recurrent VTE</caption><thead><tr><th>Variables</th><th>Univariable analysis<br>HR, 95% CI</th><th>p-value</th><th>Multivariable analysis 1<br>HR, 95% CI</th><th>p-value</th><th>Multivariable analysis 2<br>HR, 95% CI</th><th>p-value</th></tr></thead><tbody><tr><td><strong>Age range (years)</strong></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>≤ 50</td><td>Ref.</td><td></td><td>Ref.</td><td></td><td>Ref.</td><td></td></tr><tr><td>]50–65]</td><td>1.9 (1.3–2.7)</td><td>&lt; 0.001</td><td>1.6 (1.1–2.3)</td><td>0.020</td><td>1.6 (1.1–2.3)</td><td>0.019</td></tr><tr><td>> 65</td><td>2.4 (1.8–3.3)</td><td>&lt; 0.001</td><td>2.1 (1.5–3.0)</td><td>&lt; 0.001</td><td>2.2 (1.5–3.0)</td><td>&lt; 0.001</td></tr><tr><td><strong>BMI range (kg/m²)</strong></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>≤ 25</td><td>Ref.</td><td></td><td>Ref.</td><td></td><td>Ref.</td><td></td></tr><tr><td>]25–30]</td><td>1.1 (0.8–1.5)</td><td>0.48</td><td>0.9 (0.7–1.2)</td><td>0.58</td><td>0.9 (0.7–1.3)</td><td>0.69</td></tr><tr><td>]30–35]</td><td>1.1 (0.7–1.6)</td><td>0.70</td><td>1.0 (0.7–1.5)</td><td>0.90</td><td>1.0 (0.7–1.5)</td><td>0.83</td></tr><tr><td>> 35</td><td>0.6 (0.3–1.3)</td><td>0.21</td><td>0.7 (0.4–1.4)</td><td>0.31</td><td>0.7 (0.4–1.4)</td><td>0.35</td></tr><tr><td><strong>Females</strong></td><td>0.7 (0.6–0.9)</td><td>0.006</td><td>0.8 (0.6–1.1)</td><td>0.10</td><td>0.8 (0.6–1.0)</td><td>0.09</td></tr><tr><td><strong>Chronic cardiac failure history</strong></td><td>0.6 (0.3–1.2)</td><td>0.13</td><td>0.4 (0.2–0.9)</td><td>0.018</td><td>0.4 (0.2–0.8)</td><td>0.007</td></tr><tr><td><strong>Cerebral stroke</strong></td><td>0.8 (0.4–1.8)</td><td>0.58</td><td>0.6 (0.3–1.5)</td><td>0.31</td><td></td><td></td></tr><tr><td><strong>Statins</strong></td><td>1.1 (0.7–1.7)</td><td>0.69</td><td>1.0 (0.7–1.6)</td><td>0.93</td><td></td><td></td></tr><tr><td><strong>Antiplatelet agents</strong></td><td>1.0 (0.6–1.5)</td><td>0.82</td><td>0.9 (0.5–1.4)</td><td>0.51</td><td></td><td></td></tr><tr><td><strong>Smoking</strong></td><td>0.9 (0.7–1.2)</td><td>0.54</td><td></td><td></td><td></td><td></td></tr><tr><td><strong>COPD</strong></td><td>1.4 (0.9–2.2)</td><td>0.19</td><td>1.0 (0.6–1.7)</td><td>0.97</td><td></td><td></td></tr><tr><td><strong>Cancer</strong></td><td>1.8 (1.2–2.8)</td><td>0.005</td><td>2.0 (1.2–3.4)</td><td>0.008</td><td>2.0 (1.2–3.4)</td><td>0.009</td></tr><tr><td><strong>Familial history of VTE</strong></td><td>1.1 (0.8–1.5)</td><td>0.47</td><td></td><td></td><td></td><td></td></tr><tr><td><strong>Unprovoked VTE</strong></td><td>1.7 (1.3–2.2)</td><td>&lt; 0.001</td><td>2.1 (1.4–3.1)</td><td>0.001</td><td>2.0 (1.3–3.0)</td><td>0.001</td></tr><tr><td><strong>OSA history</strong></td><td>1.5 (0.7–3.0)</td><td>0.33</td><td>1.6 (0.7–3.4)</td><td>0.26</td><td>1.4 (0.6–2.9)</td><td>0.42</td></tr><tr><td><strong>OSA occurrence</strong></td><td>2.8 (0.7–11.3)</td><td>0.15</td><td>2.4 (0.6–9.8)</td><td>0.23</td><td>2.3 (0.6–9.6)</td><td>0.24</td></tr><tr><td><strong>AHI</strong></td><td>1.0082 (0.9775–1.040)</td><td>0.61</td><td></td><td></td><td></td><td></td></tr><tr><td><strong>AHI (continuous range of 10)</strong></td><td>1.1 (0.8–1.5)</td><td>0.72</td><td></td><td></td><td></td><td></td></tr><tr><td><strong>Nocturnal desaturation (hour index)</strong></td><td>0.9776 (0.9080–1.052)</td><td>0.97</td><td></td><td></td><td></td><td></td></tr><tr><td><strong>Anticoagulation duration</strong></td><td>0.9995 (0.9989–0.9999)</td><td>0.54</td><td>0.9974 (0.9989–1.0005)</td><td>0.52</td><td>0.9998 (0.9999–1.0006)</td><td>0.56</td></tr></tbody></table>

BMI body mass index, OSA Obstructive Sleep Apnea, AHI apnea hypopnea index, VTE Venous Thromboembolism Multivariable model 1 included variables associated with an increased risk of recurrence in univariable analysis and multivariable model 2 included baseline characteristics distributed differently between OSA and non-OSA patients
<table><caption>**Table 3** Phenotype of VTE</caption><thead><tr><th>Index VTE n (%)</th><th>OSA-</th><th>OSA+</th><th>p-value</th></tr></thead><tbody><tr><td>as PE with or without DVT</td><td>1117 (54.9)</td><td>51 (68.9)</td><td>0.023</td></tr><tr><td>as isolated DVT</td><td>918 (45.1)</td><td>23 (31.1)</td><td></td></tr><tr><td>Recurrent VTE n (%)</td><td></td><td></td><td>0.09</td></tr><tr><td>as PE with or without DVT</td><td>120 (49.4)</td><td>7 (77.8)</td><td></td></tr><tr><td>as isolated DVT</td><td>123 (50.6)</td><td>2 (22.2)</td><td></td></tr></tbody></table>

OSA Obstructive Sleep Apnea, VTE Venous Thromboembolism, DVT deep vein thrombosis, PE pulmonary embolism

(85.1%) vs 31 of 71 (43.7%)). The present study was not powered enough to evaluate CPAP effect on VTE recurrence risk but may have led to reducing the risk of recurrence as the majority of patients were treated. Some experimental studies suggested an endothelial dysfunction improvement with this treatment in OSA patients [34, 35]. Xie et al. [27], in a prospective study including 97 patients with 32 OSA with PE anticoagulated with warfarin during 6 months, found a higher incidence of PE recurrence after anticoagulation discontinuation in OSA patients (21.43% vs 6.78%; *p* = 0.047). Nevertheless, recurrent VTE risk factors were not collected, and OSA was less severe, with only 12.5% of OSA patients with CPAP.

The results of the present study are consistent with the “RIETE registry”: pre-existing OSA was not associated with recurrent VTE [29]. The study had several limitations: RIETE does not include information related to use of CPAP, AHI, and the relatively short follow up limited the conclusion regarding the association between long term VTE recurrence and OSA.

The clinical presentation of index VTE was significantly different between groups; there was more index PE with or without DVT in OSA patients. Recurrence as PE with or without DVT tends to be more frequent in OSA patients without reaching statistical significance. In the general population, the proportion of PE with or without DVT and DVT alone are similar [3], and DVT are more frequent as an index or recurrent VTE in unprovoked VTE [4]. A predominance of PE with or without DVT over DVT alone has also been found in chronic obstructive pulmonary disease patients suggesting an influence of respiratory disease on VTE clinical presentation [30]. The higher proportion of PE has been related to poor outcomes in the OSA population [36]; however, it was not associated with an increased risk of OSA patients’ mortality compared to non-OSA patients.

Consistent with previous studies evaluating the risk of VTE recurrence, unprovoked VTE, older age, cancer, and male gender were associated with a higher risk of VTE recurrence [4, 37–39].

The strengths of our study are related to (i) the prospective patient’s recruitment with documented VTE as

PE, with or without DVT, or isolated DVT, that were followed-up for an extended period with a median up to 4.8 (2.5–8.0) years, with scheduled clinical reevaluation every 6 or 12 months, (ii) OSA assessment in all patients based on HST or polysomnography results including AHI, nocturnal desaturation and the characteristics of apneas, (iii) the use of predefined, validated and objective criteria for all cases of recurrent VTE and predefined criteria for assessing the cause of deaths, which were adjudicated by physicians who were not involved in patient care, (iv) the multicenter design.

Several limitations should be considered. Obesity can be a confounding factor associated with VTE and OSA and might interact with its effect on recurrence. This is an observational study with data collected during a considerable period, with a random occurrence of OSA diagnosis and different sleep monitoring devices over the years. Moreover, many OSA patients included had CPAP treatment without random assignation, limiting additional evaluation of its influence and evaluating severe OSA on VTE recurrence. Sixty-four patients with OSA were excluded because on indefinite anticoagulation, the number of patients with OSA included in this study was therefore restricted. Lastly, only patients referred to the cohort centers were included in the study, they might have had more comorbidities and an index VTE with more severe clinical features than the general population with VTE. They also might have had a better prognosis due to a follow up by experienced teams with expertise in VTE, and we cannot exclude that clinical presentation have been influenced by ambulatory care of DVT.

## Conclusion

In this study, we failed to find an association between the risk of recurrent VTE, death and moderate to severe OSA after anticoagulation discontinuation. Nevertheless, larger studies are needed to evaluate OSA’s effect on VTE recurrence, given the previous evidence suggesting an association between OSA and the risk of recurrent VTE and considering the pro-coagulant state induced by intermittent hypoxemia. The effectiveness of CPAP and/or extended anticoagulation remains unknown and call for additional studies in patients with OSA and VTE.

## Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12959-021-00358-8.

**Additional file 1: eTable 1.** Risk factor for recurrent VTE with OSA pooled.

**Additional file 2: eTable 2.** Risk factors associated with mortality.

**Additional file 3: eTable 3.** Risk factors associated with mortality with OSA pooled.
## Acknowledgments

**The following institutions and nurses participated in this study:**

A. Le Brestec, A. Loussouarn, C. Daguet, Brest University Hospital Centre, Brest, France.

**Coordinating and Methods Center:**

Groupe d'Etude de la Thrombose de Bretagne Occidentale (G.E.T.B.O.), EA 3878, CIC INSERM 1412, University Hospital Centre, Brest, France.

## Authors' contributions

Dr. Le Mao had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Conception and Design: Francis Couturaud, Raphael Le Mao, Olivier Nepveu. Analysis and interpretation of the data: Olivier Nepveu, Charles Orione, Cécile Tromeur, L'heveder Cecile, Marie Guegan, Alexandre fauché, David Jimenez, Leroyer Christophe, Karine Lacut, Francis Couturaud, Raphael Le Mao. Drafting of the article: Olivier Nepveu, Charles Orione, Cécile Tromeur, L'heveder Cecile, Alexandre fauché, David Jimenez, Leroyer Christophe, Karine Lacut, Francis Couturaud, Raphael Le Mao. Critical revision of the article for important intellectual content: All. Final approval of the article: All. Provision of study material or patients: Raphael Le Mao, Olivier Nepveu, Cécile Tromeur, Cécile l'heveder, Marie Guegan, David Jimenez, Karine Lacut, Christophe Leroyer, Francis Couturaud. Obtaining of funding: Francis Couturaud, Christophe Leroyer. Administrative, technical and logistic support: Francis Couturaud, Christophe Leroyer. Collection and assembly of data: Raphael Le Mao, Francis Couturaud, Charles orione, cécile tromeur.

## Funding

This study was supported by grants from Programme Hospitalier de Recherche Clinique, France. (French Ministry of Health). Funding sources had no role relating to: the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.

## Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

## Declarations

### Ethics approval and consent to participate

This study was conducted following the amended Declaration of Helsinki. The Ethics Committee of Brest University Hospital approved the study protocol (IRB approval number: CCP Ouest 6-390). Written informed consent was obtained from all participants before inclusion.

### Consent for publication

not applicable.

### Competing interests

All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr. Nepveu declares he has no competing interests related to this research. Dr. Orione declares he has no competing interests related to this research. Dr. Tromeur declares she has no competing interests related to this research. Dr. L'heveder declares she has no competing interests related to this research. Dr. Ms. Guegan declares she has no competing interests related to this research. Dr. Lemarié declares she has competing interests related to this research. Dr. Fauché declares he has competing interests related to this research. Dr. Jimenez declares he has no competing interests related to this research. Dr. Leroyer reports having received research grant support from Pfizer and fees for board memberships or symposia from Bayer and Astra Zeneca and having received travel support from Bayer, Daiichi Sankyo, Leo Pharma, Intermune and Actelion. Dr. Lacut reports having received personal fees from Bayer-Health Care, Bristol-Myers Squibb and Boehringer Ingelheim. Dr. Couturaud reports having received research grant support from Pfizer and fees for board memberships or symposia from Bayer, Bristol-Myers Squibb/Pfizer and Astra Zeneca and having received travel support from Bayer, Bristol-Myers Squibb/Pfizer, Daiichi Sankyo, Boehringer Ingelheim, Leo Pharma, Intermune and Actelion. Dr. Le Mao declares he has no conflict of interest related to this research.

## Author details

¹Groupe d'Etude de la Thrombose de Bretagne Occidentale, UMR 1304, INSERM, Département de médecine vasculaire, interne et pneumologie, Centre hospitalo-universitaire de Brest, Université de Bretagne Occidentale, CHRU de Brest, 29609 Brest, Cedex, France. ²Centre d'Investigation Clinique INSERM 1412, Brest, France. ³Respiratory Department, Hospital Ramón y Cajal and Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.

Received: 4 October 2021 Accepted: 8 December 2021

Published online: 04 January 2022

## References

1. Goldhaber SZ, Elliott CG. Acute pulmonary embolism: part I: epidemiology, pathophysiology, and diagnosis. Circulation. 2003;108(22):2726-9. https://doi.org/10.1161/01.CIR.0000097829.89204.0C.

2. Cohen AT, Agnelli G, Anderson FA, Arcelus JI, Bergqvist D, Brecht JG, et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost. 2007;98(4):756-64. https://doi.org/10.1160/TH07-03-0212.

3. Delluc A, Tromeur C, Le Ven F, Gouillou M, Paleiron N, Bressollette L, et al. Current incidence of venous thromboembolism and comparison with 1998: a community-based study in Western France. Thromb Haemost. 2016;116(5):967-74. https://doi.org/10.1160/TH16-03-0205.

4. Khan F, Rahman A, Carrier M, Kearon C, Weitz JI, Schulman S, et al. Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis. BMJ. 2019;366:14363.

5. Rosendaal FR. Venous thrombosis: the role of genes, environment, and behavior. Hematol Am Soc Hematol Educ Program. 2005;2005(1):1-12. https://doi.org/10.1182/asheducation.V2005.1.1.1.

6. Osman AM, Carter SG, Carberry JC, Eckert DJ. Obstructive sleep apnea: current perspectives. Nat Sci Sleep. 2018;10:21-34. https://doi.org/10.2147/NSS.S124657.

7. Gozal D, Kheirandish-Gozal L. Cardiovascular morbidity in obstructive sleep apnea: oxidative stress, inflammation, and much more. Am J Respir Crit Care Med. 2008;177(4):369-75. https://doi.org/10.1164/rccm.200608-1190PP.

8. Garvey JF, Pengo MF, Drakatos P, Kent BD. Epidemiological aspects of obstructive sleep apnea. J Thorac Dis. 2015;7(5):920-9. https://doi.org/10.3978/j.issn.2072-1439.2015.04.52.

9. Heinzer R, Vat S, Marques-Vidal P, Marti-Soler H, Andries D, Tobback N, et al. Prevalence of sleep-disordered breathing in the general population: the HypnoLaus study. Lancet Respir Med. 2015;3(4):310-8. https://doi.org/10.1016/S2213-2600(15)00043-0.

10. Finkel KJ, Searleman AC, Tymkew H, Tanaka CY, Saager L, Safer-Zadeh E, et al. Prevalence of undiagnosed obstructive sleep apnea among adult surgical patients in an academic medical center. Sleep Med. 2009;10(7):753-8. https://doi.org/10.1016/j.sleep.2008.08.007.

11. Lavie P, Lavie L. Cardiovascular morbidity and mortality in obstructive sleep apnea. Curr Pharm Des. 2008;14(32):3466-73. https://doi.org/10.2174/138161208786549317.

12. Wolf J, Lewicka J, Narkiewicz K. Obstructive sleep apnea: an update on mechanisms and cardiovascular consequences. Nutr Metab Cardiovasc Dis NMCD. 2007;17(3):233-40. https://doi.org/10.1016/j.numedc.2006.12.005.

13. Jean-Louis G, Zizi F, Clark LT, Brown CD, McFarlane SI. Obstructive sleep apnea and cardiovascular disease: role of the metabolic syndrome and its components. J Clin Sleep Med JCSM Off Publ Am Acad Sleep Med. 2008;4(3):261-72.

14. Lattimore J-DL, Celermajer DS, Wilcox I. Obstructive sleep apnea and cardiovascular disease. J Am Coll Cardiol. 2003;41(9):1429-37. https://doi.org/10.1016/S0735-1097(03)00184-0.

15. Javaheri S, Barbe F, Campos-Rodriguez F, Dempsey JA, Khayat R, Javaheri S, et al. Sleep apnea: types, mechanisms, and clinical cardiovascular consequences. J Am Coll Cardiol. 2017;69(7):841-58. https://doi.org/10.1016/j.jacc.2016.11.069.

16. Sánchez-de-la-Torre M, Campos-Rodriguez F, Barbé F. Obstructive sleep apnoea and cardiovascular disease. Lancet Respir Med. 2013;1(1):61-72. https://doi.org/10.1016/S2213-2600(12)70051-6.
17. Hirosu C, Haba-Rubio J, Togeiro SM, Marques-Vidal P, Drager LF, Vollenweider P, et al. Obstructive sleep apnoea as a risk factor for incident metabolic syndrome: a joined Episono and HypnoLaus prospective cohorts study. Eur Respir J. 2018;52(5). https://doi.org/10.1183/13993003.01150-2018.

18. Riva N, Donadini MP, Ageno W. Epidemiology and pathophysiology of venous thromboembolism: similarities with atherothrombosis and the role of inflammation. Thromb Haemost. 2015;113(6):1176-83. https://doi.org/10.1160/TH14-06-0563.

19. Lippi G, Mattiuzzi C, Franchini M. Sleep apnea and venous thromboembolism. A systematic review. Thromb Haemost. 2015;114(5):958-63. https://doi.org/10.1160/TH15-03-0188.

20. García-Ortega A, Mañas E, López-Reyes R, Selma MJ, García-Sánchez A, Oscullo G, et al. Obstructive sleep apnoea and venous thromboembolism: pathophysiological links and clinical implications. Eur Respir J. 2019;53(2): 1800893. https://doi.org/10.1183/13993003.00893-2018.

21. Romero-Corral A, Caples SM, Lopez-Jimenez F, Somers VK. Interactions between obesity and obstructive sleep apnea: implications for treatment. Chest. 2010;137(3):711-9. https://doi.org/10.1378/chest.09-0360.

22. Blokhin IO, Lentz SR. Mechanisms of thrombosis in obesity. Curr Opin Hematol. 2013;20(5):437-44. https://doi.org/10.1097/MOH.0b013e3283 634443.

23. Yang G, De Staercke C, Hooper WC. The effects of obesity on venous thromboembolism: a review. Open J Prev Med. 2012;2(4):499-509. https:// doi.org/10.4236/ojpm.2012.24069.

24. Tromeur C, Le Mao R, Leven C, Couturaud F, Théreaux J, Lacut K. Diagnostic and therapeutic management of venous thromboembolic disease in obese patients. Rev Mal Respir. 2020;37(4):328-40. https://doi.org/10.1016/j.rmr.202 0.02.014.

25. Bosanquet JP, Bade BC, Zia MF, Karo A, Hassan O, Hess BT, et al. Patients with venous thromboembolism appear to have higher prevalence of obstructive sleep apnea than the general population. Clin Appl Thromb Off J Int Acad Clin Appl Thromb. 2011;17(6):E119-24. https://doi.org/10.1177/1 076029610389023.

26. Alonso-Fernández A, de la Peña M, Romero D, Piérola J, Carrera M, Barceló A, et al. Association between obstructive sleep apnea and pulmonary embolism. Mayo Clin Proc. 2013;88(6):579-87. https://doi.org/10.1016/j.ma yocp.2013.02.005.

27. Xie J, Wei Y-X, Liu S, Zhang W, Zhang X-F, Li J. Obstructive sleep apnea hypopnea syndrome as a reason for active Management of Pulmonary Embolism. Chin Med J. 2015;128(16):2147-53. https://doi.org/10.4103/0366- 6999.162498.

28. Alonso-Fernández A, Suquia AG, de la Peña M, Casitas R, Pierola J, Barceló A, et al. OSA is a risk factor for recurrent VTE. Chest. 2016;150(6):1291-301. https://doi.org/10.1016/j.chest.2016.07.011.

29. Le Mao R, Jiménez D, Bikdeli B, Porres-Aguilar M, García-Ortega A, Rosa V, et al. Prognostic Impact of Obstructive Sleep Apnea in Patients Presenting with Acute Symptomatic Pulmonary Embolism. Thromb Haemost. 2021; 121(06):808-15. https://doi.org/10.1055/s-0040-1721506.

30. Le Mao R, Tromeur C, Bazire A, Gouillou M, Guegan M, Lacut K, et al. Risk of recurrent venous thromboembolism in COPD patients: results from a prospective cohort study. Eur Respir J. 2017;50(1):1700094. https://doi.org/10.1183/13993003.00094-2017.

31. Delluc A, Tromeur C, Le Moigne E, Nowak E, Mottier D, Le Gal G, et al. Lipid lowering drugs and the risk of recurrent venous thromboembolism. Thromb Res. 2012;130(6):859-63. https://doi.org/10.1016/j.thromres.2012.08.296.

32. Orione C, Tromeur C, Mao RL, Floch P-YL, Robin P, Hoffmann C, et al. The Impact of Pulmonary Vascular Obstruction on the Risk of Recurrence of Pulmonary Embolism: A French Prospective Cohort. Thromb Haemost. 2021; Available from: http://www.thieme-connect.de/DOI/DOI?10.1055/s-0040-1 722190. [cited 2021 Feb 2].

33. Sanchez O, Benhamou Y, Bertoletti L, Constant J, Couturaud F, Delluc A, et al. Recommendations of good practice for the management of thromboembolic venous disease in adults. Short version. Rev Mal Respir. 2019;36(2):249-83. https://doi.org/10.1016/j.rmr.2019.01.003.

34. Orrù G, Storari M, Scano A, Piras V, Taibi R, Viscuso D. Obstructive sleep apnea, oxidative stress, inflammation and endothelial dysfunction-an overview of predictive laboratory biomarkers. Eur Rev Med Pharmacol Sci. 2020;24(12):6939-48. https://doi.org/10.26355/eurrev_202006_21685.

35. Schwarz EI, Puhan MA, Schlatzer C, Stradling JR, Kohler M. Effect of CPAP therapy on endothelial function in obstructive sleep apnoea: a systematic review and meta-analysis. Respiriol Carlton Vic. 2015;20(6):889-95. https://doi. org/10.1111/resp.12573.

36. Konnerth D, Schwarz F, Probst M, Seidler M, Wagner T, Faul C, et al. Is acute pulmonary embolism more severe in the presence of obstructive sleep apnea? Results from an observational cohort study. J Thromb Thrombolysis. 2018;46(2):253-9. https://doi.org/10.1007/s11239-018-1665-7.

37. Couturaud F, Sanchez O, Pernod G, Mismetti P, Jego P, Duhamel E, et al. Six months vs extended Oral anticoagulation after a first episode of pulmonary embolism: the PADIS-PE randomized clinical trial. JAMA. 2015;314(1):31-40. https://doi.org/10.1001/jama.2015.7046.

38. Heit JA, Mohr DN, Silverstein MD, Petterson TM, O'Fallon WM, Melton LJ. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med. 2000;160(6): 761-8. https://doi.org/10.1001/archinte.160.6.761.

39. Heit JA, Lahr BD, Ashrani AA, Petterson TM, Bailey KR. Predictors of venous thromboembolism recurrence, adjusted for treatments and interim exposures: a population-based case-cohort study. Thromb Res. 2015;136(2): 298-307. https://doi.org/10.1016/j.thromres.2015.06.030.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

* fast, convenient online submission

* thorough peer review by experienced researchers in your field

* rapid publication on acceptance

* support for research data, including large and complex data types

* gold Open Access which fosters wider collaboration and increased citations

* maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

BMC